Similar articles

• Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.

  Califf RM, Stump D, Topol EJ, Mark DB. Califf RM, et al. Am Heart J. 1999 May;137(5):S90-3. doi: 10.1016/s0002-8703(99)70438-2. Am Heart J. 1999. PMID: 10220606 No abstract available.
• Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.

  Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP. Kent DM, et al. J Clin Epidemiol. 2004 Aug;57(8):843-52. doi: 10.1016/j.jclinepi.2004.01.008. J Clin Epidemiol. 2004. PMID: 15485737
• Emergent decision-making: defining the patient perspective.

  Knudtson ML. Knudtson ML. Can J Cardiol. 2005 Apr;21(5):433-4. Can J Cardiol. 2005. PMID: 15861261 No abstract available.
• Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.

  Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica Mota R, Walley T, Dickson R. Boland A, et al. Health Technol Assess. 2003;7(15):1-136. doi: 10.3310/hta7150. Health Technol Assess. 2003. PMID: 12773258 No abstract available.
• From thrombolytic megatrials to clinical policy-making: facing the facts.

  Naylor CD, Armstrong PW. Naylor CD, et al. Can J Cardiol. 1995 Jun;11(6):472-6. Can J Cardiol. 1995. PMID: 7780867 Review. No abstract available.